CD163 and neoplasm: Given recent reports that the balance between effector and suppressor immune subsets may offer more useful prognostic information [5, 23–25], we evaluated the correlation between ratios of CD8+/FOXP3+, CD3+/FOXP3+, CD4+/FOXP3+, and CD68+/CD163+ and survival in tumor samples at diagnosis and after NACT.